Neutralizing and enhancing antibodies against SARS-CoV-2

Yafei Liu; Hisashi Arase

doi:10.1186/s41232-022-00233-7

Neutralizing and enhancing antibodies against SARS-CoV-2

Inflamm Regen. 2022 Dec 5;42(1):58. doi: 10.1186/s41232-022-00233-7.

Authors

Yafei Liu^{1

2}, Hisashi Arase^{3

4}

Affiliations

¹ Department of Immunochemistry, Research Institute for Microbial Diseases, Osaka University, Osaka, 565-0871, Japan.
² Laboratory of Immunochemistry, WPI Immunology Frontier Research Center, Osaka University, Osaka, 565-0871, Japan.
³ Department of Immunochemistry, Research Institute for Microbial Diseases, Osaka University, Osaka, 565-0871, Japan. arase@biken.osaka-u.ac.jp.
⁴ Laboratory of Immunochemistry, WPI Immunology Frontier Research Center, Osaka University, Osaka, 565-0871, Japan. arase@biken.osaka-u.ac.jp.

Abstract

The high transmissibility and rapid global spread of SARS-CoV-2 since 2019 has led to a huge burden on healthcare worldwide. Anti-SARS-CoV-2 neutralizing antibodies play an important role in not only protecting against infection but also in clearing the virus and are essential to providing long-term immunity. On the other hand, antibodies against the virus are not always protective. With the emergence of SARS-CoV-2 immune escape variants, vaccine design strategies as well as antibody-mediated therapeutic approaches have become more important. We review some of the findings on SARS-CoV-2 antibodies, focusing on both basic research and clinical applications.

Keywords: Enhancing antibody; Neutralizing antibody; SARS-CoV-2.

Publication types

Review

Grants and funding

JP22H04989/JSPS KAKENHI